---
title: "BIM-IOL System in Open-angle glaucoma or ocular hypertension: References"
description: "Reference list for the formulary evidence report on BIM-IOL System in Open-angle glaucoma or ocular hypertension. 129 cited documents."
canonical: "https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/references"
published: "2026-09-17T18:17:42-04:00"
modified: "2026-10-22T19:07:03-04:00"
---

# BIM-IOL System in Open-angle glaucoma or ocular hypertension: References

<a id="references"></a>

## 5 References

1. [AbbVie Durysta prescribing information (2025)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f59da84-0bcc-4c84-b3e2-e215681ef341)
2. [AbbVie Lumigan prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5e67c75-db88-4372-bb07-c8dd15c97631)
3. [Aboagye Yeboah et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13331012/)
4. [AGIS Investigators (2000)](https://pubmed.ncbi.nlm.nih.gov/11024415/)
5. [Ahmed et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35218867/)
6. [Almidani et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41106499/)
7. [Atik et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35089891/)
8. [Bacharach et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8602154/)
9. [Bartlett et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391193/)
10. [Baudouin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40113120/)
11. [Bhorade et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9429826/)
12. [Bicket et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8283665/)
13. [ClinicalTrials.gov NCT06120842](https://clinicaltrials.gov/study/NCT06120842)
14. [ClinicalTrials.gov NCT07154797](https://clinicaltrials.gov/study/NCT07154797)
15. [ClinicalTrials.gov NCT07154810](https://clinicaltrials.gov/study/NCT07154810)
16. [ClinicalTrials.gov NCT07218783](https://clinicaltrials.gov/study/NCT07218783)
17. [ClinicalTrials.gov NCT07218796](https://clinicaltrials.gov/study/NCT07218796)
18. [ClinicalTrials.gov NCT07641296](https://clinicaltrials.gov/study/NCT07641296)
19. [CMS Medicare Part B payment limit file (2026)](https://www.cms.gov/files/zip/july-2026-medicare-part-b-payment-limit-files.zip)
20. [CMS Medicare Physician and Other Practitioners CPT 92083 data (2026)](https://data.cms.gov/data-api/v1/dataset/6fea9d79-0129-4e4c-b1b8-23cd86a4f435/data?filter%5BRndrng_Prvdr_Geo_Lvl%5D=National&filter%5BHCPCS_Cd%5D=92083)
21. [CMS Medicare Physician and Other Practitioners CPT 92133 data (2026)](https://data.cms.gov/data-api/v1/dataset/6fea9d79-0129-4e4c-b1b8-23cd86a4f435/data?filter%5BRndrng_Prvdr_Geo_Lvl%5D=National&filter%5BHCPCS_Cd%5D=92133)
22. [CMS MIPS Quality ID 141 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_141_MIPSCQM.pdf)
23. [CMS MIPS Quality ID 191 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_191_MIPSCQM.pdf)
24. [CMS MIPS Quality ID 389 specification (2026)](https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2026_Measure_389_MIPSCQM.pdf)
25. [Craven et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34715397/)
26. [Cvenkel and Kolko (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12946359/)
27. [Delaney-Gesing (2025)](https://glance.eyesoneyecare.com/stories/2025-04-28/spyglass-pharma-reports-positive-18-month-data-on-glaucoma-sustained-delivery-system/)
28. [Ehrlich et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11581589/)
29. [Elam et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9252164/)
30. [Fechtner et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20386433/)
31. [Fiscella et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19354339/)
32. [Friedman et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17962457/)
33. [Garway-Heath et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25533656/)
34. [Gazzard et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6495367/)
35. [Gazzard et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36122660/)
36. [GBD 2019 Blindness and Vision Impairment Collaborators (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7820391/)
37. [Gedde et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9691551/)
38. [Gedde et al. (2026a)](https://www.aao.org/Assets/54296b7d-71f7-4813-b581-19d16b53186a/639069331666930000/primary-open-angle-glaucoma-ppp-2026)
39. [Gedde et al. (2026b)](https://www.aao.org/Assets/fb864e1c-dc05-4715-94a6-9524bf154b8d/639069328632630000/primary-open-angle-glaucoma-suspect-ppp-2026)
40. [Glaukos iDose TR approval announcement (2023)](https://www.sec.gov/Archives/edgar/data/1192448/000110465923125872/tm2332871d1_ex99-1.htm)
41. [Glaukos iDose TR prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92f6d3e2-8328-47df-972c-23008f4a1c1c)
42. [Gordon et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/12049575/)
43. [Gordon et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11362967/)
44. [Gupta et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/21336146/)
45. [Gupta et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4868098/)
46. [Halawa et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34626697/)
47. [Hattenhauer et al. (1998)](https://pubmed.ncbi.nlm.nih.gov/9818612/)
48. [Haymes et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17325158/)
49. [Heijl et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/12365904/)
50. [Heijl et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3874585/)
51. [Heijl et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37142174/)
52. [Investing.com (2026)](https://www.investing.com/news/transcripts/spyglass-pharma-at-hc-wainwright-conference-glaucoma-push-gains-ground-93CH-4900274)
53. [Jarem (2025)](https://www.aao.org/education/headline/drug-eluting-iol-may-help-expand-glaucoma-treatmen)
54. [Jonas et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28577860/)
55. [Kass et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/12049574/)
56. [Kass et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8050785/)
57. [Kholdebarin et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18711461/)
58. [Kim et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42229853/)
59. [King et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11190021/)
60. [Kolko et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39800203/)
61. [Kruoch et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12153040/)
62. [Lee et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16401779/)
63. [Leske et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12523884/)
64. [Leung et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18703943/)
65. [Li et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4695285/)
66. [Liao et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13474487/)
67. [Luo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13050984/)
68. [Mader et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37224422/)
69. [Malihi et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4038428/)
70. [Mansberger et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3426647/)
71. [McKean-Cowdin et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4864605/)
72. [Medeiros et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32544560/)
73. [Montesano et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41043781/)
74. [Myers et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12401664/)
75. [National Eye Institute (2026)](https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/glaucoma)
76. [Newman-Casey et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4485580/)
77. [Newman-Casey et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7093219/)
78. [Newman-Casey et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12947086/)
79. [NICE (2022)](https://www.nice.org.uk/guidance/ng81/chapter/Recommendations)
80. [Nordstrom et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16226511/)
81. [Ophthalmology Times (2025)](https://www.ophthalmologytimes.com/view/spyglass-pharma-releases-positive-data-from-2-trials-of-bimatoprost-drug-pad-iol-system)
82. [Ophthalmology Times (2026)](https://www.ophthalmologytimes.com/view/spyglass-pharma-reports-positive-12-month-phase-i-ii-results-for-bim-iol-system-in-glaucoma-and-ocular-hypertension)
83. [Pazos et al. (2025)](https://bjo.bmj.com/content/109/Suppl_1/1)
84. [Peters et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23932216/)
85. [Peters et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5014208/)
86. [Purola et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10732367/)
87. [Quaranta et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4920851/)
88. [Quintero et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37311015/)
89. [Rasendran et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34772873/)
90. [Rein et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/17159036/)
91. [Rein et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34560128/)
92. [Samuelson et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30880108/)
93. [Sarkisian et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38345710/)
94. [Sarkisian et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38423216/)
95. [Schoff et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11320017/)
96. [Shah et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34756939/)
97. [Shaikh et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25152501/)
98. [Shan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11544525/)
99. [Shan et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42565899/)
100. [Shih et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33352292/)
101. [Silverstein et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11947067/)
102. [Singh (2026)](https://glaucomatoday.com/articles/2026-may-june/the-bimatoprost-drug-pad-iol-system)
103. [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11512891/)
104. [Sood et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34563713/)
105. [SpyGlass Pharma 12-month Phase 1/2 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000004/exhibit991-8kpr.htm)
106. [SpyGlass Pharma 36-month FIH and 3-month Phase I/II results announcement (2025)](https://www.globenewswire.com/news-release/2025/11/10/3184483/0/en/SpyGlass-Pharma-Announces-Positive-36-Month-First-in-Human-and-3-Month-Phase-I-II-Trial-Results-for-Its-Novel-BIM-IOL-System.html)
107. [SpyGlass Pharma CPT code announcement (2026)](https://www.globenewswire.com/news-release/2026/05/18/3296580/0/en/SpyGlass-Pharma-Announces-New-Add-on-Category-III-CPT-Code-for-Its-Innovative-BIM-IOL-System.html)
108. [SpyGlass Pharma first quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000033/exhibit991-8kprx051426.htm)
109. [SpyGlass Pharma Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000020/sgp-20251231.htm)
110. [SpyGlass Pharma Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000045/sgp-20260630.htm)
111. [SpyGlass Pharma fourth quarter and full year 2025 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000018/exhibit991-8kprx032626.htm)
112. [SpyGlass Pharma IPO closing announcement (2026)](https://www.sec.gov/Archives/edgar/data/1778922/000162828026006460/exhibit991-closing8xk.htm)
113. [SpyGlass Pharma patent US12193972B2 (2025)](https://patents.google.com/patent/US12193972B2/en)
114. [SpyGlass Pharma Phase III first randomization announcement (2026)](https://www.globenewswire.com/news-release/2026/01/20/3221657/0/en/SpyGlass-Pharma-Announces-First-Patients-Randomized-in-SGP-005-and-SGP-006-Two-Registrational-Phase-III-Clinical-Trials-of-Its-Novel-BIM-IOL-System.html)
115. [SpyGlass Pharma second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1778922/000177892226000044/exhibit991-8kprx080626.htm)
116. [Stein et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3319788/)
117. [Stein et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33433580/)
118. [Tan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12901787/)
119. [Terveen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9007656/)
120. [Tham et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24974815/)
121. [Tsang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10870181/)
122. [Varma et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3206636/)
123. [Varma et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22541649/)
124. [Vision Loss Expert Group of the Global Burden of Disease Study (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11269708/)
125. [Wang et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41421762/)
126. [Weinreb et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4523637/)
127. [Yang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11342221/)
128. [Young (2024)](https://www.healio.com/news/optometry/20241126/spyglass-completes-enrollment-in-trial-of-longterm-drug-delivery-platform-for-glaucoma)
129. [Zhang et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4730948/)

## Related pages
- [BIM-IOL System: Open-angle glaucoma or ocular hypertension](https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension) · [Markdown](https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension.md)
- [BIM-IOL System in Open-angle glaucoma or ocular hypertension: Terms and abbreviations](https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/terms-and-abbreviations.md)
- [BIM-IOL System: Open-angle glaucoma or ocular hypertension](https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/executive-summary) · [Markdown](https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/executive-summary.md)
- [BIM-IOL System in Open-angle glaucoma or ocular hypertension: Product information and disease description](https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/product-information-and-disease-description.md)
- [BIM-IOL System in Open-angle glaucoma or ocular hypertension: Clinical evidence](https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/clinical-evidence.md)
- [BIM-IOL System in Open-angle glaucoma or ocular hypertension: Economic information and modeling report](https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/economics) · [Markdown](https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/economics.md)
- [BIM-IOL System in Open-angle glaucoma or ocular hypertension: prevalence by geography](https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/prevalence) · [Markdown](https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/prevalence.md)
- [BIM-IOL System in Open-angle glaucoma or ocular hypertension: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/cost-effectiveness-analyses.md)
